SRX Global to acquire CERo Therapeutics unit from CERo Therapeutics Holdings
CERO•SRX Global agreed to acquire all shares of CERo Therapeutics, a wholly owned unit of CERo Therapeutics Holdings. Consideration includes $1 million in SRX common stock, cancellation of a promissory note and assumption of about $1.56 million in liabilities.
1. Deal terms
SRX Global entered an agreement to buy all shares of CERo Therapeutics, a wholly owned operating unit of CERo Therapeutics Holdings. The consideration includes $1 million in SRX common stock, priced using the lower of the prior close or 20-day VWAP. SRX will cancel a Consolidated Senior Secured Promissory Note up to $11,666,108.77; its outstanding principal was $8,249,643.77.
2. Go-shop period
SRX will assume about $1.56 million in liabilities and provide indemnities tied to those obligations. A 30-day go-shop period allows Holdings to seek alternatives, and a superior bid must close by March 15, 2027.
